Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Summary of Changes in Contract Assets and Liabilities (Details)

v3.20.4
Collaboration and Research Arrangements - Summary of Changes in Contract Assets and Liabilities (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Disaggregation Of Revenue [Line Items]  
Accounts receivable and contract assets, Balance at Beginning of Period $ 20,158
Accounts receivable and contract assets, Additions 14,369
Accounts receivable and contract assets, Deductions 32,196
Accounts receivable and contract assets, Balance at End of Period 2,331
Contract liabilities, Balance at Beginning of Period 28,378
Contract liabilities, Additions 1,081
Contract liabilities, Deduction 7,373
Contract liabilities, Balance at End of Period 22,086
Incyte  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 8,378
Contract liabilities, Additions 335
Contract liabilities, Deduction 3,348
Contract liabilities, Balance at End of Period 5,365
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 20,000
Contract liabilities, Additions 746
Contract liabilities, Deduction 4,025
Contract liabilities, Balance at End of Period 16,721
Billed receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Accounts receivable, Balance at Beginning of Period 20,000
Accounts receivable, Additions 6,644
Accounts receivable, Deduction 26,637
Accounts receivable, Balance at End of Period 7
Unbilled receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Contract assets, Balance at Beginning of Period 158
Contract assets, Additions 7,725
Contract assets, Deduction 5,559
Contract assets, Balance at End of Period $ 2,324